Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Physiological Genomics
|
May 28, 2017
Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting
Olivia M Dong, Tim Wiltshire
Pharmacogenomics
|
April 6, 2018
Clinical pharmacogenetics: how do we ensure a favorable future for patients?
Tim Wiltshire, Olivia M Dong
Pharmacogenomics
|
September 28, 2019
Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing
Oscar Suzuki, Olivia M Dong, Rachel M Howard, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
June 2, 2022
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes
Olivia M Dong, Kevin A Friede, Catherine Chanfreau-Coffinier, et al.
Pharmacogenomics
|
July 27, 2017
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention
Mrudula S Borse, Olivia M Dong, Melissa J Polasek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 19, 2020
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
Olivia M Dong, Stephanie B Wheeler, Gracelyn Cruden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 2, 2022
Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma
Olivia M Dong, Pradeep J Poonnen, David Winski, et al.
Pharmacogenomics
|
May 26, 2018
Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients
Olivia M Dong, Amy Li, Oscar Suzuki, et al.
Journal of Personalized Medicine
|
November 27, 2021
A Cost-Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care
Charles A Brunette, Olivia M Dong, Jason L Vassy, et al.
The American Journal of Managed Care
|
February 20, 2025
Medical policy determinations for pharmacogenetic tests among US health plans
Jai N Patel, Lena Chaihorsky, Olivia M Dong, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Physiological Genomics
|
May 28, 2017
Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting
Olivia M Dong, Tim Wiltshire
Pharmacogenomics
|
April 6, 2018
Clinical pharmacogenetics: how do we ensure a favorable future for patients?
Tim Wiltshire, Olivia M Dong
Pharmacogenomics
|
September 28, 2019
Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing
Oscar Suzuki, Olivia M Dong, Rachel M Howard, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
June 2, 2022
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes
Olivia M Dong, Kevin A Friede, Catherine Chanfreau-Coffinier, et al.
Pharmacogenomics
|
July 27, 2017
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention
Mrudula S Borse, Olivia M Dong, Melissa J Polasek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 19, 2020
Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
Olivia M Dong, Stephanie B Wheeler, Gracelyn Cruden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 2, 2022
Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma
Olivia M Dong, Pradeep J Poonnen, David Winski, et al.
Pharmacogenomics
|
May 26, 2018
Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients
Olivia M Dong, Amy Li, Oscar Suzuki, et al.
Journal of Personalized Medicine
|
November 27, 2021
A Cost-Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care
Charles A Brunette, Olivia M Dong, Jason L Vassy, et al.
The American Journal of Managed Care
|
February 20, 2025
Medical policy determinations for pharmacogenetic tests among US health plans
Jai N Patel, Lena Chaihorsky, Olivia M Dong, et al.
Page
of 2